Navigation Links
Cylex Announces Significant Expansions and Reassignments of Personnel

Changes reflect increased focus on customer care and support

COLUMBIA, Md., Aug. 21 /PRNewswire/ -- Cylex(TM) is a global life sciences company that develops and manufactures research and in vitro diagnostic products based on its patented technology. Cylex is seeing continuing growth of its first marketed product, the ImmuKnow(R) assay for detection of cell-mediated immunity, and the Company believes that this product and the Company itself have still greater potential.

"The ability to fully support the needs of our customers is critical to the development of this company as a provider of diagnostic tests focused on the immune system," said Mr. Brad Stewart, the president of Cylex. "We have therefore made a series of key appointments designed primarily to address customer needs, and I am pleased to be able to announce these today."

-- Sharlene P. Blum has come to Cylex in the new position of Director, Customer Care. She had most recently held institutional and patient quality and service management positions with Quest Diagnostics. Ms. Blum is a results-oriented operations leader with over 20 years of experience in laboratory services operations management. She has also been awarded a Six Sigma Black Belt in project management.

-- Genesis E. Cautivar has joined the Company as a Laboratory Account Manager in the Customer Care group. He was previously a technical field specialist with Siemens Medical Solutions, where he focused on products used in the hematology marketplace.

-- Linyi Zhang has joined Cylex as Manager, Clinical Affairs. In this position she will focus on clinical trials of Cylex's current and development-stage products. She has over 20 years experience in biomedical research, assay development, product development, and clinical study in both academia and industry. Most recently, she was a clinical trials specialist with the National Institutes of Health. Prior to that she held various positions at Human Genome Sciences.

In addition, Cylex has appointed four new Business Development Managers, who will have regional field responsibilities for current and target customers in specific areas of the USA:

-- Hilary A. Comfort has previously held account management and sales positions with several well-known pharmaceutical and biotechnology companies, most recently including UCB Pharma and Astellas.

-- William T. Futch has come to the company from Zimmer Dental, where he was a territory manager, after additional prior field experience with Pfizer.

-- Greg Nabors brings over 15 years of field sales experience with leading pharmaceutical companies, including Aventis, Knoll Pharmaceutical and Wyeth-Ayerst Laboratories.

-- Eric G. Gann has been with Cylex since 2005 as a Laboratory Liaison and Laboratory Account Manager in the Customer Care group, and will be taking on this new role in business development.

About ImmuKnow(R)

ImmuKnow is the immune cell function assay cleared by the FDA to detect cell-mediated immunity (CMI) in adult patient populations undergoing immunosuppressive therapy for organ transplantation by measuring the concentration of adenosine triphosphate (ATP) released from CD4 cells following cell stimulation.

The ImmuKnow test is a qualitative assay and does not directly quantify the level of immunosuppression. Results of ImmuKnow assays should be used in conjunction with clinical presentation, medical history, and other clinical indicators when assessing the immune status of any individual patient.

About Cylex, Inc.

Cylex(TM) is a privately held global life sciences company that is the leader in the development and manufacture of in vitro diagnostic products intended to illuminate immunity. The Company's patented technology provides an innovative platform allowing clinical researchers to simply and reproducibly measure immune cell function for the development of new diagnostics, biomarkers, and companion assays. The Company is based in Columbia, MD, USA.

Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Multiple Independent Studies Report on Use of Cylexs Immune Cell Function Assay in Postoperative Monitoring of Kidney, Liver, and Heart Transplant Recipients
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: